

Rep. Eshoo Hosts Briefing on Follow-on Biologics

Washington, D.C. – On Friday, June 10, 2009, Rep. Anna G. Eshoo (D – CA) hosted a briefing on the cost of producing biologic drugs. At the briefing the National Venture Capital Association released a new study on cost and risks associated with biotech investment.

Earlier this year, Rep. Eshoo introduced the Pathway for Biosimilars Act which ensures a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. The bill currently has 124 bipartisan cosponsors.

To see the study that was released at briefing, [click here](#) .

To see the executive brief, [click here](#) .